Quantcast
Last updated on April 18, 2014 at 5:30 EDT

Latest Cell Therapeutics Inc. Stories

2013-01-16 04:21:07

SEATTLE, Jan. 16, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that CTI will provide a live audio and slide webcast of its analyst and investor meeting to be held on January 23 in New York. Expert speakers will focus on advances in treatment using JAK inhibitors and existing challenges in treating myelofibrosis patients. Guest speakers include: Ross L. Levine, M.D., Associate Member at Memorial Sloan-Kettering Cancer Center in the Human Oncology...

2013-01-09 04:20:57

SEATTLE, Jan. 9, 2013 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced that the Company has initiated clinical trial sites and began enrolling patients in a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor, which is being evaluated for the treatment of patients with myelofibrosis. The randomized trial is expected to enroll 270 patients and will evaluate the safety and efficacy of pacritinib compared...

2012-12-17 04:21:51

SEATTLE, Dec. 17, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced the publication of results from a preclinical study of Pixuvri(TM) (pixantrone) in the The Journal of Pharmacology and Experimental Therapeutics providing potential mechanisms for lower cardiotoxicity in patients treated with Pixuvri who received prior doxorubicin therapy. While CHOP-R is considered an effective therapy and is the standard of care in first line treatment of aggressive...

2012-12-10 04:21:28

SEATTLE, Dec. 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ: CTIC and MTA: CTIC) today announced that its Board of Directors has approved certain amendments to CTI's existing shareholder rights plan ("Rights Plan") to decrease the exercise price of the preferred stock purchase rights ("Rights") under the Rights Plan from $14.00 to $8.00 and to extend the "final expiration date" from the close of business on the third anniversary of January 7, 2010 (the "Record Date"), to the...

2012-12-10 00:20:50

SEATTLE, Dec. 10, 2012 /PRNewswire/ -- Aequus BioPharma, a majority owned subsidiary of Cell Therapeutics, Inc., announced today that Ronald J. Berenson, M.D. was appointed President and CEO of Aequus. In his new position, Dr. Berenson will expand business and product development opportunities for Aequus' GlycoPolymer technology. Aequus is currently developing its GlycoPolymer technology aimed at creating novel biopharmaceuticals with improved pharmacokinetic properties that require less...

2012-12-05 20:20:54

SEATTLE, Dec. 5, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported on interim results from a cooperative group sponsored Phase 2 clinical trial of brostallicin in combination with cisplatin for the treatment of women with metastatic triple-negative breast cancer that were presented at the San Antonio Breast Cancer Symposium (SABCS) held from December 4-8, 2012. The study enrolled women with confirmed measurable metastatic disease and triple...

2012-11-12 04:23:18

SEATTLE, Nov. 12, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, announced today the appointment of Monique Greer as Senior Vice President, Corporate Communications and Investor Relations. Ms. Greer will be responsible for leading CTI's external and internal communications strategies and will report directly to James A. Bianco, M.D., President and Chief Executive Officer. "Monique is a key hire...

2012-11-12 00:20:40

SEATTLE, Nov. 12, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that management will present at the Jefferies 2012 Global Healthcare Conference on Wednesday, November 14 at 3:00 p.m. Greenwich Meantime/ 10:00 a.m. Eastern/ 7:00 a.m. Pacific time in room Adelphi 3 at the Waldorf Hilton in London. The presentation will also be webcast live with slides, and available for replay after the presentation. The webcast can be accessed at...

2012-11-01 03:21:12

SEATTLE, Nov. 1, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported financial results for the third quarter of 2012 and recent accomplishments. Financial Results Third Quarter Results For the quarter ended September 30, 2012, total operating expenses were $14.7 million compared to $15.3 million for the same period in 2011. Net loss attributable to common shareholders was $20.2 million ($0.38 per share) for the quarter ended...

2012-10-29 15:26:26

SEATTLE, Oct. 29, 2012 /PRNewswire/ -- Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that due to severe weather on the East Coast of the United States related to Hurricane Sandy, CTI will now be releasing its financial results for the third quarter 2012 on Thursday, November 1, 2012, and will hold the related investor conference call the same day at 8:30 a.m. Eastern/1:30 p.m. Central European/5:30 a.m. Pacific Time. CTI had previously planned to announce its third...